- Topic
14k Popularity
32k Popularity
381 Popularity
165 Popularity
924 Popularity
2k Popularity
67k Popularity
122k Popularity
114 Popularity
1745k Popularity
- Pin
- Welcome Kevin_Lee to the Gate Square! 🎉
Looking forward to more great crypto insights from him.
Check out and engage with Kevin_Lee’s latest post!
👉 Post: https://www.gate.com/post/status/11758920
👉 Profile: https://www.gate.com/profile/Kevin%20Lee
Let’s give Kevin_Lee a warm welcome! 👏👏👏
- 🎯 LOT Newcomer Limited-Time Airdrop is Live!
Individual users can earn up to 1,000 LOT — share from a total prize pool of 1,000,000 LOT!
🏃 Join now: https://www.gate.com/campaigns/1294
Complete deposit and trading tasks to receive random LOT airdrops. Exclusive Alpha trading task await!🎯 LOT Newcomer Limited-Time Airdrop is Live!
Individual users can earn up to 1,000 LOT — share from a total prize pool of 1,000,000 LOT!
🏃 Join now: https://www.gate.com/campaigns/1294
Complete deposit and trading tasks to receive random LOT airdrops. Exclusive Alpha trading task await!
- 🎯 How to Earn Content Mining Rewards on Gate Post?
1️⃣ Create a post on Gate Post
2️⃣ Get likes or comments from other users
3️⃣ If those users trade (spot or futures) shortly after engaging with your post...
💰 You earn up to 10% commission on their trading fees!
📢 Share ✍️ Engage 💬 Earn 💰
- 🚀 Gate Square Creator Spark Program is Live!
We're officially recruiting the first batch of creators on Gate Square! Whether you're a crypto KOL, project team, or media outlet, join now and enjoy:
💰 Over $10,000 in monthly posting rewards
📣 Exposure to millions of Gate users
📢 Featured promotion and official support
🔥 Don't miss this early-mover advantage — apply now 👉 https://www.gate.com/questionnaire/6819
📄 More info 👉 https://www.gate.com/announcements/article/45695 - 🎉 Gate Alpha Second Points Special Airdrop is coming!
Get Token Mystery Boxes based on your Alpha Points - No points will be deducted.
📸 Alpha Points Snapshot: June 24, 16:00 (UTC)
Multi-chain trading now supported — buy on-chain assets directly with USDT!
🔗 Full details: https://www.gate.com/announcements/article/45683
Novo Nordisk: 7.2mg semaglutide phase 3 clinical trial met the primary endpoint with a weight loss of 20.7% at 72 weeks.
On January 18, Jins data reported that on January 17 local time, Novo Nordisk announced the main results of the 3b phase clinical trial STEP UP. In the STEP UP obesity trial, subcutaneous injection of 7.2mg semaglutide once a week resulted in a weight loss of 20.7% at 72 weeks, and a weight loss of 18.7% regardless of treatment compliance. The trial met its primary endpoint, with 7.2mg semaglutide showing statistically significant and superior weight loss compared to placebo at 72 weeks.